Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Elmer who wrote (1470)	8/25/2000 10:40:42 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 52153

I think that Rob is one of the best, but I don't follow any analysts. The immunogenicity of spontaneous cancers is a particular interest of mine.

To: Elmer who wrote (1470)	8/25/2000 9:12:05 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 52153

You want to find stuff like this. Find several references that have some relevance, contact some of the investigators, and ask them if they think the approach will work. I presume that DNDN will propose extending beyond the small MM market...... in that case, wave Idec's program in front of them and ask why there is rationale. Lots of new stuff in biotech is, in fact, recycled. Nonetheless, this is good news (if confirmed by other studies) for the project???....... Blood 1999 Aug 1;94(3):1070-6 V(H) gene analysis of IgM-secreting myeloma indicates an origin from a memory cell undergoing isotype switch events. Sahota SS, Garand R, Mahroof R, Smith A, Juge-Morineau N, Stevenson FK, Bataille R Molecular Immunology Group, Tenovus Laboratory, Department of Haematology, Southampton University Hospitals, Southampton, UK. ss1@sonton.ac.uk IgM-secreting plasma cell tumors are rare variants of typical isotype-switched multiple myeloma with a similar disease outcome. To probe the origin and clonal history of these tumors, we have analyzed V(H) gene sequences in 6 cases. Potentially functional tumor-derived V(H) genes were all derived from V(H)3, with the V(3-7) gene segment being used by 4 of 6. All were somatically mutated, with a mean deviation from germline sequence of 5.2% (range, 3.1% to 7.1%). The distribution of replacement mutations was consistent with antigen selection in 4 of 6 cases, and no intraclonal heterogeneity was observed. Clonally related switched isotype transcripts were sought in 4 cases, and Cgamma transcripts with tumor-derived CDR3 sequence were identified in 2 of 4. These findings indicate that IgM-secreting myelomas are arrested at a postfollicular stage at which somatic mutation has been silenced. Isotype switch variants show the cell of origin to be at the IgM to IgG switch point. These features indicate that the final neoplastic event has occurred at a stage immediately before that of typical isotype-switched myeloma. One possibility is that IgM myeloma involves the previously identified precursor cell of typical myeloma.